# US 10,500,192 B2 · Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,500,192 B2 - Document ID: US10500192B2 - Status: Granted - Kind: B2 - Application number: 15/979,041 - Filed: 2018-05-14 - Published: 2018-09-13 - Granted: 2019-12-10 - Earliest claimed: 2013-07-26 - Assignees: Race Oncology Ltd. - Applicants: Race Oncology Ltd. - Inventors: William J. Garner; Amie Franklin; John Rothman - Web page: https://patentgrep.com/patent/US10500192B2 ## CPC - A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin - A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine - A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 47/50: the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates - A61K 47/54: the modifying agent being an organic compound - A61P 35/00: Antineoplastic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof. ## Claims ### Claim 1 A method to improve the efficacy and/or reduce the side effects of suboptimally administered drug therapy comprising the steps of: (a) identifying at least one factor or parameter associated with the efficacy and/or occurrence of side effects of the drug therapy; and (b) modifying the factor or parameter to improve the efficacy and/or reduce the side effects of the drug therapy; wherein the drug therapy comprises administration of bisantrene or a derivative or analog thereof; and wherein the factor or parameter is use of bisantrene or a derivative or analog thereof in a combinatorial regime; wherein, when the use in a combinatorial regime is a use of a derivative or analog of bisantrene, the derivative or analog of bisantrene is selected from the group consisting of: (a) the analog of Formula (II) (b) the bisantrene analog of Formula (III) (c) the bisantrene analog of Formula (IV) (d) the bisantrene analog of Formula (V) (e) the bisantrene analog of Formula (VI) (f) the bisantrene analog of Formula (VII) (g) the bisantrene analog of Formula (VIII) (h) the bisantrene analog anthracen-9-ylmethylene-[2-methoxyethoxymethylsulfanyl]-5-pyridin-3-yl-[1,2,4]triazol-4-amine; (i) the bisantrene analog of Formula (X) (j) the bisantrene analog of Formula (XI) (k) the bisantrene analog of Formula (XII) (l) the bisantrene analog of Formula (XIII) (m) bisantrene analogs of Formula (XIV) wherein R1 and R3 are the same or different and are hydrogen, C1-C6 alkyl, —C(O)—R5, wherein R5 is hydrogen, C1-C6 alkyl, phenyl, mono-substituted phenyl (wherein the substituent can be ortho, meta, or para and is fluoro, nitro, C1-C6 alkyl, C1-C3 alkoxy, or cyano), pentafluorophenyl, naphthyl, furanyl, or —SO3H; wherein only one of R1 and R3 may be hydrogen or C1-C6 alkyl; R2 and R4 are the same or different and are: hydrogen, C1-C4 alkyl or —C(O)—R6, where R6 is hydrogen, C1-C6 alkyl, phenyl, mono-substituted phenyl (wherein the substituent may be in the ortho, meta, or para position and is fluoro, nitro, C1-C6 alkyl, C1-C3 alkoxy, or cyano), pentafluorophenyl, naphthyl, furanyl, or —CH2OCH3, and wherein the compounds can have the schematic structure B(Q)n, wherein B is the residue formed by removal of a hydrogen atom from one or more basic nitrogen atoms of an amine, amidine, guanidine, isourea, isothiourea, or biguanide-containing pharmaceutically active compound, and Q is hydrogen or A, wherein A is such that R′ and R″ are the same or different and are R (where R is C1-C6 alkyl, aryl, aralkyl, heteroalkyl, NC—CH2CH2—, Cl3C—CH2—, or R7OCH2CH2—, where R7 is hydrogen or C1-C6 alkyl, hydrogen, or a pharmaceutically acceptable cation or R′ and R″ are linked to form a —CH2CH2— group or a group, and n is an integer representing the number of primary or secondary basic nitrogen atoms in the compound such that at least one Q is A; (n) the bisantrene analog 9,10-bis[(2-hydroxyethyl)iminomethyl]anthracene; (o) the bisantrene analog 9,10-bis{[2-(-2-hydroxyethylamino)ethyl]iminomethyl anthracene; (p) the bisantrene analog 9,10-bis{[2-(-2-hydroxyethylamino)ethyl]iminomethyl anthracene; (q) the bisantrene analog 9,10-bis{[2-(morpholin-4-yl)ethyl]iminomethyl anthracene; (r) the bisantrene analog 9,10-bis[(2-hydroxyethyl)aminomethyl]anthracene; (s) the bisantrene analog 9,10-bis{[2-(2-hydroxyethylamino)ethyl]aminomethyl}anthracene tetrahydrochloride; (t) the bisantrene analog 9,10-bis{[2-(piperazin-1-yl)ethyl]aminomethyl}anthracene hexahydrochloride; (u) the bisantrene analog 9,10-bis{[2-(morpholin-4-yl)ethyl]aminomethyl}anthracene tetrahydrochloride; (v) N,N′-bis[2-(dimethylamino)ethyl]-9,10-anthracene-bis(methylamine); (w) N,N′-bis(1-ethyl-3-piperidinyl)-9,10-anthracene-bis(methylamine); and (x) salt forms of the compounds of (a)-(w); and wherein the drug therapy is administered to treat a form of cancer selected from the group consisting of refractory breast cancer, triple-negative breast cancer, acute myelocytic leukemia, and acute leukemias of childhood. ### Claim 2 (depends on 1) The method of claim 1 wherein the drug therapy comprises administration of bisantrene. ### Claim 3 (depends on 1) The method of claim 1 wherein the drug therapy comprises administration of a derivative or analog of bisantrene selected from the group consisting of: (a) the analog of Formula (II) (b) the bisantrene analog of Formula (III) (c) the bisantrene analog of Formula (IV) (d) the bisantrene analog of Formula (V) (e) the bisantrene analog of Formula (VI) (f) the bisantrene analog of Formula (VII) (g) the bisantrene analog of Formula (VIII) (h) the bisantrene analog anthracen-9-ylmethylene-[2-methoxyethoxymethylsulfanyl]-5-pyridin-3-yl-[1,2,4]triazol-4-amine; (i) the bisantrene analog of Formula (X) (j) the bisantrene analog of Formula (XI) (k) the bisantrene analog of Formula (XII) (l) the bisantrene analog of Formula (XIII) (m) bisantrene analogs of Formula (XIV) wherein R1 and R3 are the same or different and are hydrogen, C1-C6 alkyl, —C(O)—R5, wherein R5 is hydrogen, C1-C6 alkyl, phenyl, mono-substituted phenyl (wherein the substituent can be ortho, meta, or para and is fluoro, nitro, C1-C6 alkyl, C1-C3 alkoxy, or cyano), pentafluorophenyl, naphthyl, furanyl, or —SO3H; wherein only one of R1 and R3 may be hydrogen or C1-C6 alkyl; R2 and R4 are the same or different and are: hydrogen, C1-C4 alkyl or —C(O)—R6, where R6 is hydrogen, C1-C6 alkyl, phenyl, mono-substituted phenyl (wherein the substituent may be in the ortho, meta, or para position and is fluoro, nitro, C1-C6 alkyl, C1-C3 alkoxy, or cyano), pentafluorophenyl, naphthyl, furanyl, or —CH2OCH3, wherein the compounds can have the schematic structure B(Q)n, wherein B is the residue formed by removal of a hydrogen atom from one or more basic nitrogen atoms of an amine, amidine, guanidine, isourea, isothiourea, or biguanide-containing pharmaceutically active compound, and Q is hydrogen or A, wherein A is such that R′ and R″ are the same or different and are R (where R is C1-C6 alkyl, aryl, aralkyl, heteroalkyl, NC—CH2CH2—, Cl3C—CH2—, or R7OCH2CH2—, where R7 is hydrogen or C1-C6 alkyl, hydrogen, or a pharmaceutically acceptable cation or R′ and R″ are linked to form a —CH2CH2— group or a group, and n is an integer representing the number of primary or secondary basic nitrogen atoms in the compound such that at least one Q is A; (n) the bisantrene analog 9,10-bis[(2-hydroxyethyl)iminomethyl]anthracene; (o) the bisantrene analog 9,10-bis{[2-(-2-hydroxyethylamino)ethyl]iminomethyl}anthracene; (p) the bisantrene analog 9,10-bis{[2-(-2-hydroxyethylamino)ethyl]iminomethyl}anthracene; (q) the bisantrene analog 9,10-bis{[2-(morpholin-4-yl)ethyl]iminomethyl}anthracene; (r) the bisantrene analog 9,10-bis[(2-hydroxyethyl)aminomethyl]anthracene; (s) the bisantrene analog 9,10-bis{[2-(2-hydroxyethylamino)ethyl]aminomethyl}anthracene tetrahydrochloride; (t) the bisantrene analog 9,10-bis{[2-(piperazin-1-yl)ethyl]aminomethyl}anthracene hexahydrochloride; (u) the bisantrene analog 9,10-bis{[2-(morpholin-4-yl)ethyl]aminomethyl}anthracene tetrahydrochloride; (v) N,N′-bis[2-(dimethylamino)ethyl]-9,10-anthracene-bis(methylamine); (w) N,N′-bis(1-ethyl-3-piperidinyl)-9,10-anthracene-bis(methylamine); and (x) salt forms of the compounds of (a)-(w). ### Claim 4 (depends on 1) The method of claim 1 wherein the drug therapy is administered to treat cancer, and wherein the cancer is a form of cancer selected from the group consisting of refractory breast cancer and triple-negative breast cancer. ### Claim 5 (depends on 1) The method of claim 1 wherein the combinatorial regime is a combinatorial regime selected from the group consisting of: (a) use in a combinatorial regime as a chemotherapeutic agent with at least one agent inducing immunoactivity; (b) use in a combinatorial regime as a chemotherapeutic agent with at least one agent inducing macrophage activation; (c) use in a combinatorial regime as a chemotherapeutic agent with at least one cytokine; (d) use in a combinatorial regime as a chemotherapeutic agent with at least one agent inhibiting telomerase; (e) use in a combinatorial regime as a chemotherapeutic agent with at least one agent inhibiting survivin; (f) use in a combinatorial regime as a chemotherapeutic agent with at least one agent inducing demethylation; (g) use in a combinatorial regime as a chemotherapeutic agent with at least one adjuvant; (h) use in a combinatorial regime as a chemotherapeutic agent with at least one antibody; (i) use in a combinatorial regime as a chemotherapeutic agent with at least one innate or adaptive immune stimulator; (j) use in a combinatorial regime as a chemotherapeutic agent with at least one checkpoint inhibitor; (k) use in a combinatorial regime as a chemotherapeutic agent with at least one mTOR antagonist; (l) use in a combinatorial regime as a chemotherapeutic agent with at least one Akt inhibitor; (m) use in a combinatorial regime as a chemotherapeutic agent with at least one notch inhibitor; (n) use in a combinatorial regime as a chemotherapeutic agent with at least one HSP inhibitor; (o) use in a combinatorial regime as a chemotherapeutic agent with at least one phosphatidylinositide 3-kinase inhibitor; (p) use in a combinatorial regime as a chemotherapeutic agent with at least one kinase inhibitor; (q) use in a combinatorial regime as a chemotherapeutic agent with cytarabine; (r) use in a combinatorial regime as a chemotherapeutic agent with taxane; (s) use in a combinatorial regime as a chemotherapeutic agent with taxol; (t) use in a combinatorial regime as an agent inducing macrophage activation with at least one agent inducing telomerase inhibition; (u) use in a combinatorial regime as an agent inducing macrophage activation with at least one cytokine; (v) use in a combinatorial regime as an agent inducing macrophage activation with at least one agent inhibiting survivin; (w) use in a combinatorial regime as an agent inducing macrophage activation with at least one agent inducing demethylation; (x) use in a combinatorial regime as an agent inducing macrophage activation with at least one adjuvant; (y) use in a combinatorial regime as an agent inducing macrophage activation with at least one antibody; (z) use in a combinatorial regime as an agent inducing macrophage activation with at least one innate or adaptive immune stimulator; (aa) use in a combinatorial regime as an agent inducing macrophage activation with at least one checkpoint inhibitor; (ab) use in a combinatorial regime as an agent inducing macrophage activation with at least one mTOR antagonist; (ac) use in a combinatorial regime as an agent inducing macrophage activation with at least one Akt inhibitor; (ad) use in a combinatorial regime as an agent inducing macrophage activation with at least one notch inhibitor; (ae) use in a combinatorial regime as an agent inducing macrophage activation with at least one HSP inhibitor; (af) use in a combinatorial regime as an agent inducing macrophage activation with at least one phosphatidylinositide 3-kinase inhibitor; (ag) use in a combinatorial regime as an agent inducing macrophage activation with at least one kinase inhibitor; (ah) use in a combinatorial regime as an agent inducing macrophage activation with cytarabine; (aj) use in a combinatorial regime as an agent inducing macrophage activation with taxane; and (ak) use in a combinatorial regime as an agent inducing macrophage activation with taxol.